Our observations suggest that SARS-CoV-2-specific CD4+ and CD8+ T-cell responses should be considered to better evaluate vaccination and public health strategies, and assessed together with neutralizing antibody titers to predict protection from infection and severe COVID-19. The gene discussed is CD8A; the disease is infection.